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Covalent  attachment  of  NO  to the  ﬁrst approved  HIV  protease  inhibitor  Saquinavir  (Saq-NO)  expands
the  therapeutic  potential  of the original  drug.  Apart  from  retained  antiviral  activity,  the modiﬁed  drug
exerts  strong  antitumor  effects  and  lower  toxicity.  In  the  present  study,  we  have evaluated  the  sen-
sitivity  of different  hematological  malignancies  to Saq-NO.  Saq-NO  efﬁciently  diminished  the  viability
of  Jurkat,  Raji,  HL-60  and  K562  cells.  While  Jurkat  and  Raji  cells  (established  from  pediatric  patients)
displayed  abrogated  proliferative  potential,  HL-60  and K652  cells  (originated  from  adults)  exposed  to
Saq-NO  treatment  underwent  caspase  dependent  apoptosis.  In addition,  similar  sensitivity  to Saq-NO
was  observed  in  mononuclear  blood  cells  obtained  from  pediatric  patients  with  acute  lymphoblastic
leukemia  (ALL)  and adult  patients  with  acute  myeloid  leukemia  (AML).  Western  blot  analysis  indicated
p70S6  kinase  as  a possible  intracellular  target  of Saq-NO  action.  Moreover,  the  addition  of  a NO  moiety  to
Lopinavir  resulted  in  improved  antitumor  potential  as  compared  to  the  parental  compound,  suggesting
that  NO-derived  HIV  protease  inhibitors  are  a potential  new  source  of anticancer  drugs  with  unique  mode
of action.
©  2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Over the last few decades many discoveries have been achieved
in the ﬁeld of cancer therapy, and in particular in the area of
small molecule inhibitors of oncogenic cell signaling pathways [1].
Unfortunately, therapy failure due to relapsed or primary resistant
disease is still frequent and is associated to severe toxicity and side
effects [2]. Thus, further studies are warranted to identify novel
anticancer compounds with similar mode of action but with lower
toxicity. Drugs used for the treatment of viral infection such as HIV
protease inhibitors (HPIs) may  represent a promising therapeutic
option in the cancer setting [3]. Their anticancer properties were
incidentally noticed when it was observed that patients exposed to
∗ Corresponding author at: Department of Biomedical Sciences and Biotechnology,
University of Catania, Via Androne 83, 95124 Catania, Italy.
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HPIs, exhibited signiﬁcantly lower rate of HIV associated cancers
[3]. Independently of HIV protease inhibition, these drugs reduce
angiogenesis, cell invasion and viability of malignant cell through
induction of apoptosis/autophagy, accompanied with Akt inhibi-
tion [4–11]. Beside their effectiveness on solid cancers, HPIs were
found efﬁcient in the treatment of blood cancers [12–14]. Ritona-
vir induced apoptosis and inhibited NF-kB activity in adult T cell
leukemia. Ritonavir, Saquinavir (Saq) and Nelﬁnavir through their
inactivation of STAT3 and ERK1/2 led to growth arrest and apo-
ptosis of human multiple myeloma cells [15]. Nelﬁnavir was also
found to induce mitochondria independent apoptosis of leukemia
cell lines and impaired proteasome activity and proliferation of
multiple myeloma cells in vitro and in vivo [16]. Importantly, Saq
displayed antiproliferative activity even against imatinib-resistant
chronic myelogenous leukemia cell lines [6]. Beside direct effects,
HPIs are able to potentiate the effect of 1,25-dihydroxyvitamin D3
or ATR on myelioid leukemia cells [14,17]. Recently, Kraus et al. [12]
demonstrated that Nelﬁnavir augments proteasome inhibition by
http://dx.doi.org/10.1016/j.leukres.2015.06.013
0145-2126/© 2015 Elsevier Ltd. All rights reserved.
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Bortezomib and overcomes Bortezomib and Carﬁlzomib resistance
[12]. Limitations of the usage of HPIs are toxicity and development
of resistance. Different chemical manipulation like packaging in
nanostructured lipid carriers [18] has been examined to reduce tox-
icity. We  focused our attention on a derivative of Saq obtained by
the linkage of the NO moiety as NO-hybridization has found useful
to increase the anticancer potential in the case of nonsteroidal anti-
inﬂammatory drugs [19]. Saquinavir-NO (Saq-NO) was found to be
signiﬁcantly superior than Saq in diminishing the viability of a vari-
ety of adherent tumor cell lines in vitro and abrogating the growth
of melanoma, prostate and colon cancer in syngeneic and xenograft
models in vivo [20–25]. Although in p53 deﬁcient and iNOS positive
cell lines, Saq-NO induced apoptotic cell death, its antitumor action
was mostly executed through blockade of cellular proliferation of
cancer cells and reversion to normal phenotype through process of
differentiation or transdifferentiation [20–22]. Additional beneﬁt
of this drug is its potential to sensitize tumor cells to chemother-
apeutics and antitumor immune responses [22,25–27]. We also
demonstrated that the mechanism of action of Saq-NO is partly
based on the property to inhibit the activation of p70S6K protein
that is important for many cellular processes, transcription, trans-
lation, protein and lipid synthesis, cell growth and metabolism [25].
In this paper, we have studied the effects of Saq-NO on differ-
ent blood cancers. We  found that Saq-NO efﬁciently suppressed
the expansion of lymphoma and leukemia cell lines in vitro. More-
over, Saq-NO decreased the viability of malignant cells isolated
from patients with acute lymphoblast leukemia and acute myeloid
leukemia. To the best of our knowledge, this is the ﬁrst evidence of
efﬁcacy of modiﬁed HIV protease inhibitors against blood cancers.
2. Materials and methods
2.1. Reagents
Fetal calf serum (FCS), RPMI-1640, phosphate-buffered saline (PBS), dimethyl
sulfoxide (DMSO), and propidium iodide (PI) were attained from Sigma (St. Louis,
MO). Annexin V-FITC (AnnV) was from Biotium (Hayward, CA). Acridine orange
(AO) was from Labo-Moderna (Paris, France). The Jurkat, Raji, HL-60 and K562
cell  lines were purchased from ATCC. Cells were routinely maintained in HEPES-
buffered RPMI-1640 medium supplemented with 10% FCS, 2 mM l-glutamine, 0.01%
sodium pyruvate, and antibiotics (culture medium) at 37 ◦C in a humidiﬁed atmo-
sphere with 5% CO2. Cells were seeded at 1 × 104/well in 96-well plates for viability
determination and 2.5 × 105/well in 6-well plate for ﬂow cytometry.
2.2. Isolation of peripheral blood mononuclear cells (PBMC)
Heparinized blood was  obtained from ALL and AML  patients before chemother-
apy treatment and healthy volunteers, centrifuged at 115 × g 10 min  and plasma
were layered on 4 ml lymphocyte separation medium. Samples were centrifuged
for 20 min  at 800 × g without brake and the interface layer ring was collected care-
fully. Cell suspension was washed twice in PBS 10 min  at 700 × g. Finally, cells were
resuspended in RPMI-1640-10% FCS. Cells were counted in Turk solution while try-
pan blue staining was used for viability judgment. The study was  approved by the
Ethics Review Board of Clinical Center “Dr Dragisa Misovic” (01-10000/6) and Insti-
tute for Health Care of Mother and Child of Serbia “Dr Vukan Cupic” (970/3). Cell
samples from humans were obtained after written informed consent.
2.3. Acidic phosphatase assay
Cells (1 × 105 cells/well) in 100 l of culture medium were cultivated in the
presence of a wide range of concentrations of tested drugs for 48 h. At the end of
treatment, the cells were incubated in the presence of the substrate for acidic phos-
phatase (1.1 mg/ml  p-nitro-phenyl-phosphate, 0.4% Triton-X, 0.3% Na-acetate) for
2  h at 37 ◦C. The reaction was terminated by the addition of 50 l 1.3 M NaOH. The
absorbance of developed dye was read at 405 nm by using an automatic microplate
reader (LKB) [28].
2.4. Cell cycle analysis
The cells (2.5 × 105/well) were exposed to the IC50 doses of each NO-modiﬁed
drugs and equal dose of parental drug for 48 h, then ﬁxed in 70% ethanol at 4 ◦C over
night. After washing in PBS, the cells were incubated with PI (20 g/ml) and RNase
(0.1 mg/ml) for 30 min at 37 ◦C in the dark [20]. Red ﬂuorescence was analyzed with
FACS Calibur ﬂow cytometer (BD, Heidelberg, Germany). The distribution of cells in
different cell cycle phases was determined with Cell Quest Pro software (BD).
2.5. Annexin V-FITC/PI and apostat staining
The cells (2.5 × 105/well) were treated with IC50 dose of each compound or
equal dose of the parental drug for 48 h, then stained with AnnV-FITC/PI (Biotium,
Hayward, CA) or apostat (R&D Systems, Minneapolis, MN USA) following the man-
ufacturer’s instructions. Cells were analyzed with FACS Calibur ﬂow cytometer (BD,
Heidelberg, Germany) using Cell Quest Pro software (BD).
2.6. CFSE staining
The cells were stained with 1 M of carboxyﬂuoresceinsuccinimidyl ester (CFSE)
for  10 min  at 37 ◦C, then washed and treated with IC50 dose of the tested compounds
for 96 h. At the end of cultivation, the cells were washed and analyzed with FACS
Calibur ﬂow cytometer [20].
2.7. Western blot analysis
The cells were treated with an IC50 dose of Saq-NO and equal dose of Saq for 2,
6,  12 and 18 h and lysed in protein lysis buffer containing 62.5 mM Tris–HCl (pH
6.8  at 25 ◦C), 2% (w/v) SDS, 10% glycerol, 50 mM dithiothreitol, and 0.01% (w/v)
bromophenol blue. The samples were then electrophoretically separated on 12%
SDS-polyacrylamide gel. PageRuler prestained ladder (Thermo scientiﬁc, USA) was
used as protein molecular weight marker. Electrotransfer to polyvinylidene diﬂuo-
ride  membranes at 5 mA/cm2 was done using a semidry blotting system (Fastblot
B43; Bio-Rad, Goettingen, Germany). The membranes were blocked with 5% (w/v)
BSA  in PBS with 0.1% Tween 20, and then blots were incubated with speciﬁc antibod-
ies to p-S6 (Ser240/244), S6, p-p70S6K (Thr389), p-p70S6K (Thr421/Ser424), p70S6K
and  tubulin (Cell Signaling Technology, Danvers, MA), followed by incubation with
secondary antibody (ECL donkey anti-rabbit horseradish peroxidase-linked; GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Bands were visualized using a
chemiluminescence detection system (ECL; GE Healthcare).
2.8. Bioinformatical analysis of primary sequence homology
Amino acid sequences of desired proteins were obtained from NCBI PubMed
database. Homology region in protein primary sequence was analyzed using BLASTP
2.2.28 program [29,30].
2.9. Statistical analysis
The results of cellular viability are presented as means ± SD from three
independent experiments. The signiﬁcance of the differences between vari-
ous treatments was assessed by analysis of variance (ANOVA), followed by a
Student–Newman–Keuls test. Two-tailed matched pair Student’s t test was per-
formed to compare effects of Saq and Saq-NO on primary cancer cell lines,
Mann–Whitney test was used to compare the effect of Saq and Saq-NO on pediatric
vs  adults patients. A p value less than 0.05 was considered signiﬁcant.
3. Results
3.1. Saq-NO decreased the viability of blood cancer cell lines
In order to test the efﬁcacy of Saq-NO in blood cancers, four
different human cell lines were chosen: T lymphoblastic leukemia
– Jurkat, Burkitt’s lymphoma – Raji, erythroleukemia – K562 and
promyelocytic leukemia HL-60. The cells were exposed to a range
of concentrations of Saq and Saq-NO and after 48 h their viabil-
ity was  measured by acidic phosphatase test. Both drugs exerted
marked antitumoral effects in all the cell lines tested (Fig. 1). Saq-
NO showed signiﬁcant lower IC50 values than Saq with the lowest
IC50 obtained on HL-60 cells. Sensitivity of blood cancer cell lines
to Saq-NO were even higher than previously identiﬁed in adher-
ent tumor cell lines [20,21,23,25]. Interestingly, for Jurkat, Raji and
K562 cells, higher concentrations of Saq resulted more efﬁcient
than similar concentration of Saq-NO, while the opposite situa-
tion is observed at lower concentrations. Indeed, in contrast to the
results observed with HL60 cells, a plateau effect was  observed
upon the treatment of Jurkat, Raji and K562 cells with Saq-NO,
indicating that further dose enhancement of Saq-NO was  not in
correlation with the decrease of cell viability.
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Fig. 1. Saq-NO diminished the viability of blood cancer cells. Cells were exposed to various concentrations of tested drugs and after 48 h, cell viability was determined by
acidic  phosphatase assay. The data are presented as mean ± SD from three independent experiments. *p < 0.05, refers to controls.
3.2. The modality of action of Saq-NO is deﬁned by cell speciﬁcity
Our previous data demonstrated that Saq-NO primarily dis-
played cytostatic potential against tumor cells. To evaluate the
mechanism responsible for the decreased viability, cell cycle
analysis was performed after 48 h of treatment with equimolar
concentrations of Saq-NO and of parental drug. As seen in Fig. 2A,
Saq-NO treatment was associated with an increased percentage of
hypodiploid subpopulation in HL-60 and K562 cells as compared to
Saq. Only insigniﬁcant percentage of apoptotic cells were observed
in Jurkat and Raji cells upon treatment with both Saq-NO and Saq.
Since the lower number of viable cells upon the treatment might be
a consequence of suppressed proliferation, these cells were stained
with CFSE and analyzed after 96 h of incubation with Saq or Saq-
NO (Fig. 2B). While both control and Saq-treated cultures almost
completely divided, less than 20% of cells retained their prolifera-
tive capacity after exposure to Saq-NO. A similar effect was  seen
for K562 and HL-60 cells where upon treatment with Saq-NO only
6.8% and 4.6% of cells, respectively, proliferated (as compared to
the 80% and 95% of divided control cells, respectively). Annexin/PI
staining demonstrated that Saq-NO treatment of HL-60 and K562
cells resulted in augmented percentage of both early and late apop-
totic cells conﬁrming that the drug triggered the apoptotic process
in these cells (Fig. 2C). Accordingly apostat staining detected cas-
pase activation in both HL-60 (mean ﬂuorescence 31.8 vs. 16.3 as
compared to control cells) and K562 cells (mean ﬂuorescence 39.5
vs. 22.2 as compared to control cells). On the other hand, treatment
of Jurkat and Raji cells with Saq-NO led to insigniﬁcant apoptosis
(4.8% of early and 1.4% of late apoptotic vs. 3.7% and 1.0% in control
Jurkat cells; 5.3% of early and 1.9% of late apoptotic vs. 2.5% and
0.5% in control Raji cells). Taken together, these data support the
concept that cell speciﬁcity deﬁnes the mode of the drug action.
3.3. Saq-NO decreased the viability of mononuclear blood cells
isolated from the patients with ALL and AML
The capacity of Saq-NO to reduce the viability of malignant cells
obtained from untreated pediatric patients with T lymphoblastic
leukemia (T-ALL) and untreated adult patients with acute myeloid
leukemia (AML) were determined. The cells were isolated from
peripheral blood and were examined in the same experimental
conditions as previously described. IC50 values for Saq-NO and
Saq in children (Table 1) and adult (Table 2) cell cultures were
higher than those observed in corresponding cell lines, but were
lower than the IC50 values obtained for the blood of healthy vol-
unteers (53.15 ± 14.26 M,  n = 4). Importantly, Saq-NO displayed
higher activity against patients’ blood cells in comparison to the
original drug (p = 0.02 for adults and p = 0.05 for pediatric patients).
Interestingly, Saq-NO was  equally effective on the cells obtained
from patients sensitive and resistant to steroid therapy, which is
an indicator of bad prognosis (Table 1). Higher efﬁcacy of Saq-NO
against adults (average IC50 = 17.6 + 12.6) in comparison to pedi-
atric (average IC50 = 33.2 + 19.7) patients (p = 0.06) is probably due
to its potential to abolish the malignant cells resistance to apopto-
sis which is one of the hallmarks of adult acute myeloid leukemia
[31] (Table 2).
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Fig. 2. Effects of Saq-NO in blood cancer cell lines. Cells were treated to IC50 dose of Saq-NO and equal dose of Saq and after 48 h cell cycle analysis was performed (A),
alternatively CFSE stained Jurkat (left) and Raji (right) cells were analyzed after 96 h of treatment (B). HL-60 (left) and K562 (right) cells were stained by Ann/PI upon 48 h of
treatment (C).
3.4. Saq-NO permanently inhibited p70S6 kinase expression
Saq is designed as a peptidomimetic drug created to block the
proteolytic activity of the HIV protease and prevent formation of
infective viral particles [3]. Subsequently, it was  discovered that Saq
and Saq-NO affected mammalian cell physiology, indicating their
ability to functionally modulate different intracellular molecules.
To predict possible interactions between Saq-NO and key
1092 D. Maksimovic-Ivanic et al. / Leukemia Research 39 (2015) 1088–1095
Table  1
Characteristics of ALL patients and effects of Saq and Saq-NO on isolated PBMC.
Sex/age Disease Risk WBC  × 109/l Blasts (%) LDH PR IC50 Saq (M) IC50 Saq-NO (M)
F/2 ALL IR 35.7 90 4740 Good 49 30
M/4  ALL IR 70.2 94 2676 Good 127 43
M/15  ALL T HR 77.2 96 10,120 Poor 84 31
M/10 ALL IR 7.65 37 1882 Good 37 30.9
M/4  ALL IR 9.75 49 924 Good 14.2 9.3
F/6  ALL IR 2.01 67 821 Good 61 75
M/15  CML/ALL HR 163 12 2050 Poor 34 16
M/17  ALL IR 10.3 90 1089 Good 109 31
players in signal transduction, we performed bioinformatic analysis
of homology regions between active site of HIV protease and impor-
tant signaling molecules in cancer cells. This evaluation revealed
that there is no homology with Akt, ERK1/2, p70S6K2 and S6 pro-
tein (Suppl. 1). However, certain homologies were found within
autoinhibitory domain of p70S6K1 (Suppl. 2).
Since multiple phosphorylations at the autoinhibitory domain
are required, the possible inﬂuence of Saq or Saq-NO on p70S6K
function was analyzed by Western blot. Analysis was  performed
in Jurkat and HL-60 cells at indicated time points after exposure to
Saq or Saq-NO. A strong and persistent inhibition of Thr421/Ser424
phosphorylation was detected after treatment with Saq-NO in both
cell lines (Fig. 3). In parallel, a strong but reversible, abrogation
of S6K phosphorylation at position Thr389 was observed upon
the treatment with original compound in both tested cell lines.
Finally, phosphorylation of downstream target of S6K, S6 protein,
was noticeably reduced by Saq-NO in both – Jurkat and HL-60 cells.
As compared to Saq-NO, Saq selectively downregulated S6 activity
in HL-60 but not in Jurkat cells. However, after normalization to
the house-keeping protein – tubulin, this effect disappears (Suppl.
3). This is the consequence of enhancement of total amount of S6
protein. Given the observation time for the experiment, this effect
is likely due to increased S6 mRNA stability rather than de novo
transcription.
3.5. Modiﬁed HIV protease inhibitors are promising candidates
for the treatment of hematological malignancies
To determine whether the anticancer properties of Saq-NO
were unique, the HIV protease inhibitor Lopinavir was  modiﬁed
by attachment of a NO moiety. Jurkat, Raji and K562 cell lines
were treated with various concentrations of the parental and
NO-modiﬁed drugs for 48 h and then the IC50 values were deter-
mined (Table 3). While both drugs exhibited anticancer potential,
the effects of Lopinavir-NO were less potent than those previ-
ously observed for Saq-NO. For estimation of the IC50 values of
Lopinavir-NO, the effects of equimolar concentrations of Lopinavir
and Lopinavir-NO were examined. Strong inhibition of cellular
proliferation was observed upon the treatment with modiﬁed
drug (Table 3). Lopinavir-NO induced caspase dependent apoptosis
(Table 3). In summary, these data indicated that NO-derived HIV
protease inhibitors may  represent promising candidate for blood
cancer treatment.
4. Discussion
Covalent attachment of NO to the ﬁrst approved HIV protease
inhibitor Saq induces numerous advantages to original drug. While
the novel compound retained the antiviral potential of parental
drug, its efﬁcacy against different cancer cell lines, as well as in syn-
geneic and xenograft solid tumor models was markedly enhanced
[20–25]. Saq-NO also appeared to be signiﬁcantly less toxic than Saq
both in vitro and in vivo. Thus a new chemical entity endowed with
higher anticancer potential and lower toxicity than the parental
drug was generated by hybridization with NO.  [20,25]. The lower
toxicity of Saq-NO could be at least partly ascribed to its cytostatic
activity based on inhibited proliferation followed by differentiation
toward more mature phenotype as opposed to cancer cell apopto-
sis [20,25]. This type of antitumor action eliminates compensatory
proliferation as a response of anaplastic cells to the death of cells
in neighborhood [32]. At the molecular level, general loss of Saq
toxicity could be associated with the fact that Saq-NO does not
compromise Akt function, that might be responsible for numerous
side effects observed upon the treatment with original compound
such as development of diabetes, and osteoporosis [3]. Although
the inhibition of Akt by Saq was  linked to its antitumor potential,
the NO-modiﬁed form of the drug possesses even higher capacity to
suppress tumor progression without Akt down-regulation [20,25].
Recent studies elaborated the possibility that the leading target
of Saq-NO belongs to downstream part of the PI3K-Akt signaling
pathway, focusing the attention to S6 protein inhibition [20,25].
The results presented here extend the list of tumor cells
examined for the effects of Saq-NO to hematological cancers. Raji
and Jurkat cell lines were both developed from pediatric patients.
Saq-NO suppressed proliferation in both cell lines but neither
underwent to apoptosis. The iNOS+ K562 cells were developed
from an adult patient with chronic myelogenous leukemia. The p53
null HL-60 cell line resembles acute promyelocytic leukemia cell.
Saq-NO suppressed proliferation and induced caspase dependent
apoptosis in both K562 and HL-60 cells. The different mechanism
of action exerted by Saq-NO in Jurkat/Raji vs K562/HL-60 cells is
in concordance with the previously observed feature of Saq-NO to
inhibit the proliferation without induction of death in numerous
Table 2
Characteristics of AML patients and effects of Saq and Saq-NO on isolated PBMC.
Sex/age FAB AML  type WBC  × 109/l Blasts (%) sLDH (U/l) IC50 Saq (M) IC50 Saq-NO (M)
F/60 M2  81.6 25 1642 48.2 5.8
F/56  M5  109.7 73 3316 51.9 7.9
M/77  M2  21.8 5 264 62.8 28.6
F/87  M4  65 90 458 1.2 0.9
F/71  M2  124 23 2673 54.0 27.0
F/61  M2  14.5 50 678 25.7 16.1
F/80  M2  84 38 2471 61.6 17.9
F/90  M4  70 21 682 79.7 37.3
FAB, French–American–British classiﬁcation; WBC, white blood count; LDH, lactate dehydrogenase (normal range 160–410 U/l); AraC, arabinoside cytosine.
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Fig. 3. Saq-NO inhibited the expression of p70S6K. Jurkat (A) and HL-60 (B) cells were exposed to IC50 dose of Saq-NO and equal dose of Saq and expression of p70S6K and
S6  protein were analyzed by Western blot. Representative data from one of three independent experiments are presented.
cancer cell lines with exception of p53 mutant or iNOS positive
cells [21,22]. The fact that Saq-NO promoted intensive apoptosis
in cell lines originated from adults but not from pediatric patients,
could be explained by general difference in pathogenesis between
pediatric and adult blood cancers. In addition, the potential of
Saq-NO was presently conﬁrmed in experiments performed
with human material isolated from the pediatric patients with
ALL which is the most frequent malignant disease in childhood,
accounting 25% of all malignant disease in pediatric patients. In
fact, evaluation of blood samples obtained from adult AML  patients
revealed good responses to the treatment with Saq-NO, although
at higher concentrations than those found effective in other cancer
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Table  3
Antitumor potential of Lopinavir-NO.
Cell line Lopi Lopi-NO Control
IC50 SubG % of apop. casp act. IC50 SubG % of apop. casp act. SubG % of apop. casp act.
Raji 18 0.65 2.3 106.33 10 9.31 43.4 124.52 0.7 3 72.5
Jurkat 33 1.01 5.7 92 14 10.18 18 122 1.52 4.7 73.7
K562  36.5 1.1 5.2 23.9 18.5 18.7 19.1 32.2 0.6 1 22.2
cell lines or cells from adult patients with blood cancer. The fact
that higher IC50 values were observed on patients’ blood cells
than in cancer cell lines may  be the consequence of the presence
of heterogeneous cellular population in tested samples that are
collectively referred as mononuclear cells but with a percentage
of malignant clones that varied from sample to sample. Because of
that we believe that results obtained on cell lines used as a model
for these blood cancers and that show signiﬁcantly lower IC50
values than those observed in blood patients are much appropriate
for comparison and possibly more predictable for translation of
in vitro ﬁndings to the clinical setting. The high IC50 necessary to
exert antitumoral effects on blood cells from human patients may
raise a concern about the possible utilization of Saq and Saq-NO
to treat leukemia. In fact, the plasma concentrations of Saq vary
according to the dose administrated, but values reported do not
generally exceed 10 M.  Although this might make it difﬁcult to
consider a role for Saq in the treatment of these conditions, we
do not believe that this jeopardizes the possible use of Saq-NO
in this setting. In fact, the lower toxicity of Saq-NO that we have
previously demonstrated in vitro and in vivo [20] may  allow
the use of doses higher than the parental compound which may
achieve plasma levels higher than 10 M.  In addition, we have
previously demonstrated that Saq-NO, unlike Saq, exerts synergis-
tic potential with other commonly used chemotherapeutic drugs
[22–24].
The therapeutic potential of Saq-NO in AML  is ampliﬁed by the
fact that this disease is often initially insensitive to chemother-
apy [31]. The excellent response to Saq-NO treatment observed in
primary AML cells is very promising especially in light of the fact
that patients whose blood cells were treated with Saq-NO, devel-
oped early resistance to subsequent chemotherapy (not shown).
Resistance to apoptosis is one of the hallmarks of adult blood
cancer in both chronic and acute form [31]. Therapy based on
induction of apoptosis is usually ineffective. In contrast, pedi-
atric ALL patients are often successfully treated with cytostatic
drugs, indicating that malignant hyper-proliferation is not accom-
panied with compromised sensitivity to apoptosis but rather
connected with inadequate development of autoregulatory mecha-
nisms involved in limitation of immune responses [32]. Saq-NO was
able to limit proliferation in both, pediatric and adults clones. How-
ever, in cell lines generated from adults, the compound promoted
apoptosis.
Analysis of the molecular mechanisms of drug action revealed
the role of p70S6K and its downstream targets. It was recently
found that targeting of mTOR signaling pathway represents a
promising approach in treatment of different hematologic malig-
nancies [33–35]. The over-expression and/or enhanced activation
of proteins involved in the initiation of translation have been
shown to induce a malignant phenotype [36]. As p70S6K is a key
molecule in this cascade, its inhibition by speciﬁc small molecules
became of great therapeutic interest for protein synthesis block-
age and subsequent decrease in cell proliferation [37]. Recent
data, as well as data presented in this study, clearly indicated
the powerful afﬁnity of Saq-NO to block malignant cell division
through high binding afﬁnity to a domain of this speciﬁc kinase,
preventing its activation. It was previously demonstrated that
ability of Saq-NO to inhibit androgen-dependent prostate cancer
proliferation was not enhanced by further addition of the mTORC1
blocker rapamycin [25]. This, also lends indirect support to the
concept that Saq-NO abrogated p70S6K activation through phos-
phorylation of auto-inhibitory domain and prevented subsequent
conformational changes of the enzyme, necessary for its complete
activation. Analysis of homology between HIV protease active site
and important actors of main signaling pathways revealed presence
of homology sequences in autoinhibitory domain of p70S6K1, but
not in Akt, S6, p70S6K2 and ERK1/2. Saq-NO remarkably inhibited
multiple phosphorylations of p70S6K auto-inhibitory and linker
domains in both cell lines – Jurkat and HL60. This, further, reﬂected
on its downstream activity. The ability of Saq-NO to abolish apop-
totic resistant phenotype and sensitize cells to apoptosis triggered
by chemotherapy as well as immune system mediated cytotoxicity
previously described in melanoma, androgen dependent and inde-
pendent prostate cancers as well as non-small lung cancer, could
be explained by its ability to compromise S6K dependent processes
[21,23,24]. Intracellular sensitization to apoptosis is mainly associ-
ated to abrogated level of natural caspase inhibitors, which belongs
to the group of proteins regulated by p70S6K. In addition, Saq-NO
can enhance the expression of functional membrane death recep-
tor speciﬁc for TRAIL-DR as well as inhibit the activity of multidrug
resistant pumps (MDRs) more potently than the commercial MDR
inhibitor Dexverapamil [26].
Permanent blockage of this important kinase was  observed
in both Jurkat and HL60 cell line and has numerous repercus-
sions on the behavior of proliferative cells. However, in resting,
non-proliferative cells, p70S6K1 is associated with eIF3 com-
plex which centrally regulates protein synthesis [38]. Therefore
Saq-NO-induced inhibition of eIF3 activity explains why Saq-
NO is basically an antiproliferative drug with limited toxicity
toward non-proliferative cells. It is evident that Saq-NO remark-
ably inhibited p70S6K phosphorylation in both Jurkat and HL60 cell
lines. However, on the contrary to the expected inhibition of the
downstream S6 protein observed in Jurkat cells, an increase in its
phosphorylation levels was observed in HL-60 upon normalization
to tubulin. This effect is due to an unexpected upregulation of total
S6 protein. It was  previously shown that commitment of HL-60 cells
to proliferate or differentiate into monocytic/macrophage or gran-
ulocytic linage is deﬁned by mRNA stability for ribosomal proteins
[39]. Elevated phosphorylation levels of S6 in HL-60 cells have
been already described by Couldwel et al. in connection with PKC
depletion [40]. Interestingly, impressive similarities were found by
bioinformatics analysis between HIV protease active site with the
members of PKC family especially with epsilon isoform (Suppl. 1).
This discovery brings a new light on our understanding of Saq/Saq-
NO intracellular activities. In parallel with this, PKC inhibition is
tightly related to induction of apoptosis [40]. Connection between
PKC inhibition, S6 activation and apoptosis indicated the possibility
that PKC, besides S6K1 was affected by Saq-NO. This interaction as
well as its consequences will be the subject of future study.
Finally, Saq is the ﬁrst approved HIV inhibitor and ﬁrst
NO-modiﬁed compound in a group of HIV protease inhibitors
with demonstrated antitumoral potential. The observations that
Lopinavir and importantly the enhanced ability of NO-modiﬁed
Lopinavir to exert signiﬁcant anti-cancer activities against blood
cancer cells, points out the signiﬁcant novel potential of this group
D. Maksimovic-Ivanic et al. / Leukemia Research 39 (2015) 1088–1095 1095
of antiviral drugs and of the related compounds obtained via the
addition of NO moieties, to the ﬁeld of oncotherapy.
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